Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas

Dueñas Jiménez, J.; Candanedo Arellano, A.; Santerre, A.; Orozco Suárez, S.; Sandoval Sánchez, H.; Feria Romero, I.; López-Elizalde, R.; Alonso Venegas, M.; Netel, B.; Torre Valdovinos, B.; Dueñas Jiménez, S.
September 2014
Journal of Neuro-Oncology;Sep2014, Vol. 119 Issue 2, p275
Academic Journal
Estrogens are oncogenic hormones at a high level in breast, prostate, endometrial and lung cancer. Estrogens are synthesized by aromatase which has been used as a biomarker both in breast and lung cancer. Estrogen biological activities are executed by their classic receptors (ERα and ERβ). ERα has been described as a cancer promoter and ERβ, as a possible tumor suppressor. Both receptors are present at low levels in primary multiforme glioblastoma (GBM). The GBM frequency is 50 % higher in men than in women. The GBM patient survival period ranges from 7 to 18 months. The purpose of this pilot study was to evaluate aromatase and estrogen receptor expression, as well as 17ß-estradiol concentration in astrocytoma patients biopsies to obtain a prognosis biomarker for these patients. We analyzed 36 biopsies of astrocytoma patients with a different grade (I-IV) of malignity. Aromatase and estrogen receptor mRNA expression were analyzed by semiquantitative RT-PCR, and the E2 levels, by ELISA. E2 concentration was higher in GBM, compared to grade II or III astrocytomas. The number of cells immunoreactive to aromatase and estrogen receptors decreased as the grade of tumor malignity increased. Aromatase mRNA expression was present in all biopsies, regardless of malignity grade or patient age or gender. The highest expression of aromatase mRNA in GBM patients was associated to the worst survival prognostic (6.28 months). In contrast lowest expression of ERα mRNA in astrocytoma patients had a worst prognosis. In conclusion, aromatase and ERα expression could be used as prognosis biomarkers for astrocytoma patients.


Related Articles

  • Estrogen receptor β promoter methylation: a potential indicator of malignant changes in breast cancer. Lei Gao; Xiaolong Qi; Kaiwen Hu; Ruili Zhu; Wei Xu; Shipeng Sun; Lixin Zhang; Ximing Yang; Baojin Hua; Guijian Liu; Gao, Lei; Qi, Xiaolong; Hu, Kaiwen; Zhu, Ruili; Xu, Wei; Sun, Shipeng; Zhang, Lixin; Yang, Ximing; Hua, Baojin; Liu, Guijian // Archives of Medical Science;Feb2016, Vol. 12 Issue 1, p129 

    Introduction: Estrogen receptor β (ERβ) always lacks expression in estrogen-dependent tumors, which may result from gene inactivation by methylation. In this study, we aimed to determine whether aberrant methylation of the ERβ promoter is associated with decreased ERβ...

  • Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. Loi, Sherene; Haibe-Kains, Benjamin; Desmedt, Christine; Wirapati, Pratyaksha; Lallemand, Françoise; Tutt, Andrew M.; Gillet, Cheryl; Ellis, Paul; Ryder, Kenneth; Reid, James F.; Daidone, Maria G.; Pierotti, Marco A.; Berns, Els M. J. J.; Jansen, Maurice P. H. M.; Foekens, John A.; Delorenzi, Mauro; Bontempi, Gianluca; Piccart, Martine J.; Sotiriou, Christos // BMC Genomics;2008, Vol. 9, Special section p1 

    Background: Estrogen receptor positive (ER+) breast cancers (BC) are heterogeneous with regard to their clinical behavior and response to therapies. The ER is currently the best predictor of response to the anti-estrogen agent tamoxifen, yet up to 30-40% of ER+BC will relapse despite tamoxifen...

  • MicroRNAs as Novel Biomarkers for Breast Cancer. Heneghan, H. M.; Miller, N.; Lowery, A. J.; Sweeney, K. J.; Kerin, M. J. // Journal of Oncology;2010, p1 

    Breast cancer is a complex phenotypically diverse genetic disease, involving a variety of changes in gene expression and structure. Recent advances in molecular profiling technology have made great progress in unravelling the molecular taxonomy of breast cancer, which has shed new light on the...

  • Molecular prognostic factors: clinical implications in patients with breast cancer. Tonini, Giuseppe; Fratto, Maria Elisabetta; Schiavon, Gaia // Cancer Therapy;2008, Vol. 6 Issue 2, p773 

    Many molecular markers have been recently identified as prognostic and predictive factors in patients with breast cancer. Histological type, grading, tumor size, lymph node involvement, and estrogen receptor a (ER) and HER-2 receptor status all influence prognosis and the probability of response...

  • Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Flågeng, M. Hauglid; Haugan Moi, L. L.; Dixon, J. M.; Geisler, J.; Lien, E. A.; Miller, W. R.; Lønning, P. E.; Mellgren, G.; Flågeng, M Hauglid; Moi, L L Haugan; Lønning, P E // British Journal of Cancer;10/20/2009, Vol. 101 Issue 8, p1253 

    Background: Acquired resistance to endocrine therapy in breast cancer is poorly understood. Characterisation of the molecular response to aromatase inhibitors in breast cancer tissue may provide important information regarding development of oestrogen hypersensitivity....

  • Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Hefti, Marco M.; Hu, Rong; Knoblauch, Nicholas W.; Collins, Laura C.; Haibe-Kains, Benjamin; Tamimi, Rulla M.; Beck, Andrew H. // Breast Cancer Research;2013, Vol. 15 Issue 4, p1 

    Introduction: Estrogen receptor (ER) and progesterone receptor (PR) testing are performed in the evaluation of breast cancer. While the clinical utility of ER as a predictive biomarker to identify patients likely to benefit from hormonal therapy is well-established, the added value of PR is less...

  • Molecular functions and significance of the MTA family in hormone-independent cancer. Ning, Zhifeng; Gan, Jinfeng; Chen, Chaoying; Zhang, Dianzheng; Zhang, Hao // Cancer & Metastasis Reviews;Dec2014, Vol. 33 Issue 4, p901 

    The members of the metastasis-associated protein (MTA) family play pivotal roles in both physiological and pathophysiological processes, especially in cancer development and metastasis, and their role as master regulators has come to light. Due to the fact that they were first identified as...

  • High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Riaz, Muhammad; Sieuwerts, Anieta M.; Look, Maxime P.; Timmermans, Mieke A.; Smid, Marcel; Foekens, John A.; Martens, John W.M. // Breast Cancer Research;2012, Vol. 14 Issue 5, p1 

    Introduction: The TWIST homolog 1 (TWIST1) is a transcription factor that induces epithelial to mesenchymal transition (EMT), a key process in metastasis. The purpose of this study was to investigate whether TWIST1 expression predicts disease progression in a large breast cancer cohort with...

  • Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Fuxiao Xin; Meng Li; Curt Balch; Michael Thomson; Meiyun Fan; Yunlong Liu; Scott M. Hammond; Sun Kim; Kenneth P. Nephew // Bioinformatics;Feb2009, Vol. 25 Issue 4, p430 

    Motivation: Recent evidence shows significant involvement of microRNAs (miRNAs) in the initiation and progression of numerous cancers; however, the role of these in tumor drug resistance remains unknown. Results: By comparing global miRNA and mRNA expression patterns, we examined the role of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics